"弹弹弹，弹走鱼尾纹"，这句曾风靡一时的广告语，至今仍是许多人的共同记忆。背后公司"丸美"，近日正计划赴港二次上市。 这家成立于2002年的企业，历经五年冲刺后于2019年成功登陆A股。然而上市后其业绩"变脸"，2020年至2022年净利润连续三年下滑，其 中2021年跌幅高达47.95%，直至2023年才有所回升。 回顾历史过往，这是一家曾争议缠身的公司。近期，丸美因财务核算不准确、相关会计科目存在错误列报、募集资金使用不规范等问 题，被证监局处罚，同时，公司董事长孙怀庆、董事会秘书程迪、公司财务总监王开慧被出具警示函，为此次冲刺蒙上阴影。 目前，丸美在A股的股价为33.16元/股，总市值约133亿元。 01 一半收入用于销售，研发占比不到3% 首先来看看丸美的财务情况。和不少国内美妆品牌类似，丸美也出现了"重营销、轻研发"、增收不增利的现象。 根据招股书，2022年到2024年、2025年前9个月，丸美公司收入分别为17.3亿、22.3亿、29.7亿及24.5亿，净利润分别为1.7亿、2.8亿、3.4 亿及2.5亿。 尽管2025年9个月的收入超出了2023年全年两个亿，但净利润却少了0.3亿。 来源/丸 ...

Core Viewpoint - The company Marubi, known for its beauty products, is planning a secondary listing in Hong Kong after facing financial and governance issues following its initial public offering in A-shares in 2019. The company has experienced a decline in net profit from 2020 to 2022, with a significant drop of 47.95% in 2021, although there has been a recovery in 2023 [1][3]. Financial Performance - Marubi's revenue for the years 2022 to 2024 and the first nine months of 2025 is projected to be 1.73 billion, 2.23 billion, 2.97 billion, and 2.45 billion respectively, with net profits of 170 million, 280 million, 340 million, and 250 million [3]. - The company's revenue is primarily generated from its two brands, Marubi and Lianhuo, with Marubi contributing 70-80% of total revenue. Lianhuo's revenue is expected to grow from 290 million in 2022 to 900 million in 2024 [5]. - Despite an increase in overall gross margin from 67.8% in 2022 to 74.8% in the first nine months of 2025, the net profit margin has remained around 10% due to rising sales and distribution expenses, which increased from 850 million in 2022 to 1.63 billion in 2024 [6]. Governance and Compliance Issues - Marubi has faced scrutiny for financial irregularities, including inaccurate revenue recognition and improper accounting practices. The company has been penalized for these issues, which include misreporting funds held in third-party payment platforms and misclassifying consulting fees as research and development expenses [10][11]. - The management of raised funds has also been criticized, as Marubi failed to separate the accounting for projects funded by raised capital from those funded by its own resources, leading to non-compliance with regulations [11][15]. Dividend Practices - Since its IPO in 2019, Marubi has distributed cash dividends totaling 1.08 billion, with significant amounts flowing to the founder and his spouse, raising concerns about the sustainability of such practices in relation to the company's financial health [16][19]. Brand Trust and Historical Controversies - Marubi has a history of controversies, including misleading claims about its Japanese origins and product quality issues. Although these past issues have diminished in public discourse, current concerns have shifted to financial data integrity and governance practices [30][31].

近日，上海神奇制药（维权）投资管理股份有限公司（以下简称"神奇制药"）的一则补税公告，再次将 这家药企推至舆论风口。其子公司贵州柏强制药因自查涉税问题，需补缴企业所得税及滞纳金约 1667.12万元。尽管公司声称"不涉及行政处罚"，且款项已缴纳完毕，但结合其近年业绩滑坡、监管处 罚频发等情况，此次事件折射出的深层风险值得警惕。 补税背后：盈利承压与税务合规之困 补缴金额虽已结清，但对神奇制药而言并非小数目。2025年前三季度，公司归母净利润为5030万元，此 次补税及滞纳金约占其中的33%，显著侵蚀当期利润。贵州柏强制药作为其三大主要子公司之一，上半 年营收3.40亿元、净利润2480万元，补税规模可见一斑。 更令人关注的是，公司未在公告中详细说明"漏水"原因，仅表示补缴款项将计入2025年当期损益。这种 模糊处理易引发市场对该公司财务内控及税务管理规范的质疑，尤其是在医药行业税务监管持续收紧的 背景下，合规能力将成为企业稳健经营的重要基石。 治理隐忧：曾被监管点名，内控漏洞频现 此次补税事件并非神奇制药首次陷入负面舆情。今年9月，公司因2023年利用已停止的"基药宣传计 划"套取销售费用4483.83万元， ...

Core Viewpoint - The company, Aier Eye Hospital, addressed investor inquiries regarding its optical services, tax policies, and financial practices, emphasizing transparency and adherence to regulations [1]. Financial Practices - Aier Eye Hospital confirmed that it follows a unified accounting policy across its subsidiaries and adheres to the "Basic Norms for Internal Control of Enterprises" [1]. - The company conducts self-assessments and supervision of its internal controls and hires independent accounting firms annually to audit its financial report controls [1]. Tax Policies - The company indicated that details regarding its business accounting and tax policies are disclosed in its annual and interim reports, inviting investors to review these documents for comprehensive information [1]. Medical Services - Aier Eye Hospital acknowledged the inquiries about its compliance with medical service pricing regulations and the specific medical services it offers that meet insurance and tax requirements, although specific services were not detailed in the response [1].

Core Viewpoint - The article highlights the potential risks and challenges faced by Hengtong Optical, a company seeking to go public on the Beijing Stock Exchange, including issues related to overseas subsidiaries, high customer concentration, declining R&D investment, and pressure from performance agreements [1][3]. Group 1: Overseas Subsidiary Issues - Hengtong Optical has a complex situation with its overseas subsidiaries, including instances of shareholding proxies in Singapore and Thailand [4]. - Regulatory authorities are concerned about the shareholding proxy arrangements and have requested detailed explanations regarding the unbundling process and compliance with overseas investment regulations [5][7]. Group 2: Performance Agreement Pressures - The company's IPO is significantly influenced by a performance agreement that mandates share buyback obligations, which are suspended only upon the acceptance of the IPO application [8]. - If the IPO fails or is withdrawn, the buyback obligations will be reinstated, placing immense pressure on the actual controller, Chen Jianwei, to ensure a successful IPO [9]. Group 3: Customer Concentration Risks - Hengtong Optical exhibits a high dependency on major customers, with nearly 80% of sales in the first half of 2025 coming from the top five clients, and the largest client, AFL, accounting for 58.22% [10][11]. - This dependency has increased over the year, raising concerns about the company's operational independence, as AFL is also the primary supplier [12]. Group 4: Revenue Authenticity Concerns - The Beijing Stock Exchange has raised questions regarding the authenticity of Hengtong Optical's revenue growth, noting that sales to AFL have surged disproportionately compared to AFL's own revenue growth [14][15][16]. Group 5: Declining R&D Investment - Hengtong Optical's R&D expenditure has decreased from 7.26% in 2022 to 4% in 2024, significantly below industry averages [17][19]. - The company has a low percentage of employees with higher education, which may hinder its innovation capabilities [20]. Group 6: Financial Control Issues - The company has faced multiple financial control issues, including instances of related parties making payments on its behalf and using personal accounts for company transactions [21][22]. Group 7: Deteriorating Debt Servicing Ability - Hengtong Optical's liquidity ratios have worsened, with the current ratio dropping from 1.98 in 2022 to 1.17 in 2024, and the quick ratio falling to 0.85 [24]. - The company's debt-to-asset ratio has increased significantly, indicating a higher financial risk compared to industry averages [26]. Group 8: Supplier Concerns - One of Hengtong Optical's main suppliers, Shenzhen Huatianda Information Technology Co., Ltd., reported zero employees insured, raising questions about the legitimacy of transactions with this supplier [28][30]. Group 9: Fundraising Challenges - The company has reduced its fundraising target from 651 million yuan to 494 million yuan, a decrease of 24%, indicating a lack of market confidence [31]. - Despite the reduced fundraising, the company has distributed cash dividends totaling 37.13 million yuan during the reporting period, contrasting with its need for liquidity [33].

Core Viewpoint - MiFu Technology (Zhejiang) Co., Ltd. is addressing governance issues and financial internal control irregularities as part of its IPO review process, while reporting positive revenue and profit growth projections for the upcoming years [3][4]. Company Governance - The actual controllers of MiFu Technology, Gu Qiang, Gu Liugui, and Wang Naijun, collectively control 86.31% of the company's shares, with noted familial relationships among them [3]. - The company has acknowledged governance irregularities, including fund occupation, and is required to explain its governance system and the effectiveness of its rectification measures [3]. Financial Performance - MiFu Technology's main business involves the R&D, production, and sales of key components for automotive fluid pipeline systems and other plastic parts, applicable to both new energy vehicles and traditional fuel vehicles [4]. - Revenue projections for 2022 to 2024 are as follows: 138 million yuan, 202 million yuan, and 273 million yuan, respectively, with net profits of approximately 36.34 million yuan, 58.17 million yuan, and 76.22 million yuan [4]. Financial Metrics - Total assets as of December 31, 2024, are projected to be approximately 523.66 million yuan, up from 320.08 million yuan in 2023 and 235.26 million yuan in 2022 [5]. - The company’s debt-to-asset ratio is expected to decrease from 24.65% in 2023 to 18.88% in 2024, indicating improved financial stability [5]. - The gross profit margin is projected to be 45.31% in 2024, slightly down from 47.43% in 2023, while the net profit margin is expected to remain strong [5].

Core Viewpoint - Ningbo Nengzhiguang New Material Technology Co., Ltd. is facing scrutiny ahead of its IPO on the Beijing Stock Exchange due to significant discrepancies in its financial performance and internal control issues, raising concerns about the sustainability of its growth and the integrity of its financial reporting [1][8][12]. Financial Performance - From 2022 to 2024, the company's compound annual growth rate (CAGR) for net profit excluding non-recurring items reached 79.3%, while revenue growth was only 4.88% [3][6]. - In Q1 2025, the company reported a revenue decline of 3.53% to 133 million yuan and a net profit drop of 23.21% to 11.89 million yuan, raising questions about its profitability stability [1][8]. - The company attributed the 2023 profit surge to an increase in gross margin, which rose from 12.03% in 2022 to 16.85% in 2023, but this has been met with skepticism from regulators [8][12]. Internal Control Issues - The company has faced significant internal control deficiencies, including the use of employee personal accounts to collect customer deposits, amounting to 711,300 yuan, which has been flagged as a violation of financial management practices [2][12]. - Despite claims of rectification, the persistence of internal control issues has led to doubts about the company's financial compliance and governance [12][14]. - The actual controller's daughter initially refused to provide financial transaction records, citing personal privacy, which raised further concerns about transparency [9][10][11]. Regulatory Scrutiny - The Beijing Stock Exchange has issued inquiries regarding the company's financial data, particularly the unusual profit spikes in 2023 and the subsequent decline in 2025, questioning the sustainability of its growth and the authenticity of its financial practices [1][8][12]. - The company is required to demonstrate the legitimacy of its financial performance and address concerns about potential profit manipulation or one-time gains [8][12].